High-Grade Prostate Cancer: Favorable Results in the Modern Era Regardless of Initial Treatment

Table 2

Comparison of outcome measures by pretreatment features and primary treatment.

	Outcome measures
	5-year OS	𝑃 value^1	5-year BFFS	𝑃 value^1	5-year CSS	𝑃 value^1
Gleason score
8	77.2%	0.71	75.6%	<0.001	96.1%	0.001
9	74%		58.2%		95.9%
10	70.6%		41.2%		76.5%
Pretreatment PSA (ng/mL)
<10	80.7%	0.002	72.1%	0.001	98%	<0.001
10–20	83.3%		61.1%		100%
>20	63.6%		51.1%		84.1%
Extent of disease at diagnosis
Unilateral	79.7%	0.53	67.8%	0.54	97.2%	0.28
Bilateral	77%		64.9%		95%
Percentage of positive cores
<50%	79.8%	0.30	71.3%	0.02	95.7%	0.69
≥50%	75.5%		60.6%		94.9%
Months from diagnosis to treatment
<3	76.5%	0.08	62.6%	0.29	94.2%	0.43
3–12	81.6%		70.2%		97.2%
>12	60%		70%		95%

¹OS: Overall Survival; BFFS: Biochemical Failure-Free Survival; MFS: Metastasis-Free Survival; CSS: Cancer-Specific Survival.
²Pearson’s Chi-Square test.